SORT BY PROGRAM

Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with blaOXA-48
Publication Date
September 24, 2024
September 24, 2024

Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22
Publication Date
September 17, 2024
September 17, 2024

Cefepime-Taniborbactam: A Novel Cephalosporin/b-Lactamase Inhibitor Combination
Publication Date
August 30, 2024
August 30, 2024

Pharmacodynamics of Taniborbactam in Combination with Cefepime Studied in an In Vitro Model of Infection
Publication Date
August 13, 2024
August 13, 2024

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime
Publication Date
August 12, 2024
August 12, 2024

Novel Antibiotics for Urinary Tract Infection (UTI): The EAGLE-2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI
Publication Date
August 6, 2024
August 6, 2024

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection
Publication Date
May 23, 2024
May 23, 2024

In Vitro Activity of Cefepime/Taniborbactam and Comparator Agents Against Gram-negative Bacterial Bloodstream Pathogens Recovered from Patients with Cancer
Publication Date
April 10, 2024
April 10, 2024

Cefepime-Taniborbactam in Complicated Urinary Tract Infection
Publication Date
February 14, 2024
February 14, 2024

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States
Publication Date
September 28, 2023
September 28, 2023

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection
Publication Date
March 21, 2023
March 21, 2023

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
Publication Date
January 16, 2023
January 16, 2023

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/ taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
Publication Date
January 14, 2023
January 14, 2023

Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects
Publication Date
December 19, 2022
December 19, 2022

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
Publication Date
August 3, 2022
August 3, 2022

In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain
Publication Date
March 15, 2022
March 15, 2022

Activity of cefepime-taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19
Publication Date
February 7, 2022
February 7, 2022

Clinical exposure–response relationship of cefepime-taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model
Publication Date
November 8, 2021
November 8, 2021

In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates
Publication Date
November 8, 2021
November 8, 2021

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
Publication Date
October 18, 2021
October 18, 2021

The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli
Publication Date
September 8, 2021
September 8, 2021

Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays
Publication Date
March 18, 2021
March 18, 2021

Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales
Publication Date
November 24, 2020
November 24, 2020

Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria
Publication Date
October 9, 2020
October 9, 2020

Metallo-Beta-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline
Publication Date
September 21, 2020
September 21, 2020

In vivo pharmacodynamics of new-generation beta-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-beta-lactamase-producing Gram-negative bacteria
Publication Date
August 30, 2020
August 30, 2020

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
Publication Date
July 15, 2020
July 15, 2020

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-Beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Publication Date
December 23, 2019
December 23, 2019

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-Beta-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
Publication Date
November 25, 2019
November 25, 2019

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
Publication Date
August 27, 2019
August 27, 2019

Interplay between beta-lactamases and new beta-lactamase inhibitors
Publication Date
March 5, 2019
March 5, 2019